Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
China flag China · Delayed Price · Currency is CNY
61.66
-2.77 (-4.30%)
Nov 17, 2026, 3:00 PM CST

Beijing Hotgen Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
462.9395.46505544.623,5325,307
Other Revenue
9.429.424.783.2224.4162.65
472.32404.88509.78547.843,5575,369
Revenue Growth
9.55%-20.58%-6.95%-84.60%-33.76%945.54%
Cost of Revenue
177.87179.6255.94211.721,7662,254
Gross Profit
294.44225.28253.84336.111,7903,116
Selling, General & Admin
395.54326.16294.62258.6483.58404.26
Research & Development
230.38162.28166.14132.88191.14131.92
Other Operating Expenses
5.523.863.453.589.25.04
Operating Expenses
648.7499.51465.58381.66695.26541.92
Operating Income
-354.26-274.23-211.74-45.551,0952,574
Interest Expense
-15.74-8.8-1.81-1.01-2.32-1.27
Interest & Investment Income
19.8782.1142.3339.5934.5234.26
Currency Exchange Gain (Loss)
-2.27-2.27-0.784.314.95-14.64
Other Non Operating Income (Expenses)
-1.041.360.22-1.273.31-4.82
EBT Excluding Unusual Items
-353.44-201.84-171.77-3.921,1352,587
Gain (Loss) on Sale of Investments
-23.34-37.762.49-23.687.523.12
Gain (Loss) on Sale of Assets
0.560.58-1.63-0.64-0.34-14.21
Asset Writedown
-38.51-38.14-61.02-41.79-70.06-8.51
Other Unusual Items
9.929.896.585.022.6314.22
Pretax Income
-404.81-267.28-225.4314.991,0752,582
Income Tax Expense
-12.73-8.648.07-1.73150.1379.44
Earnings From Continuing Operations
-392.08-258.63-233.4916.71925.122,202
Minority Interest in Earnings
92.9842.5927.7312.2119.62-16.61
Net Income
-299.1-216.05-205.7728.92944.742,186
Net Income to Common
-299.1-216.05-205.7728.92944.742,186
Net Income Growth
----96.94%-56.78%1850.41%
Shares Outstanding (Basic)
959287889192
Shares Outstanding (Diluted)
959287889292
Shares Change
12.66%4.99%-1.29%-3.88%-0.14%-0.12%
EPS (Basic)
-3.15-2.36-2.360.3310.3323.75
EPS (Diluted)
-3.15-2.36-2.360.3310.2823.75
EPS Growth
----96.81%-56.72%1852.80%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-295.8-126.93-142.98-461.9413.542,246
Free Cash Flow Per Share
-3.11-1.39-1.64-5.234.5024.40
Dividend Per Share
---0.200-3.378
Dividend Growth
-----233.34%
Gross Margin
62.34%55.64%49.79%61.35%50.34%58.03%
Operating Margin
-75.00%-67.73%-41.53%-8.31%30.79%47.93%
Profit Margin
-63.32%-53.36%-40.36%5.28%26.56%40.71%
Free Cash Flow Margin
-62.63%-31.35%-28.05%-84.31%11.63%41.82%
EBITDA
-279.66-193.98-123.9515.661,1842,631
EBITDA Margin
-59.21%-47.91%-24.31%2.86%33.30%49.00%
D&A For EBITDA
74.680.2587.7961.289.3957.5
EBIT
-354.26-274.23-211.74-45.551,0952,574
EBIT Margin
-75.00%-67.73%-41.53%-8.31%30.79%47.93%
Effective Tax Rate
----13.96%14.70%
Revenue as Reported
472.32404.88509.78547.843,5575,369
Advertising Expenses
-45.2515.5913.3855.0868.41